Status:
COMPLETED
Effect Of Rilapladib (SB-659032) On Platelet Aggregation
Lead Sponsor:
GlaxoSmithKline
Conditions:
Healthy Subjects
Atherosclerosis
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.
Eligibility Criteria
Inclusion
- Subjects with QTc \< 450 msec as measured at screening.
Exclusion
- History of asthma.
- Smokers.
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT00387257
Start Date
October 1 2006
End Date
April 1 2007
Last Update
April 15 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Randwick, New South Wales, Australia, 2031